Insiders · TBPH

TBPH insider transactions

Theravance Biopharma Inc. (TBPH) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

TBPH insiders

Everyone who has filed a Form 3, 4, 5 or 144 at Theravance Biopharma Inc., latest first. Follow anyone to get their next filing.

• Weiss Asset Management LPFormer 10% Owner, since September 2022
• Deepika PakianathanDirector
• Donal O'ConnorDirector
• Dean J MitchellDirector
• Susannah GrayDirector, since February 2023
• Alsup Laurie SmaldoneDirector
• Rick E WinninghamChief Executive Officer, Director-$560K
• Aziz SawafSVP & Chief Financial Officer, since January 2023
• Aine MillerSVP, Dev & Head of Ire Office, since February 2024
• Brett A. GrimaudSVP, Gen Counsel and Secretary, since February 2023
• Rhonda FarnumSVP, Comm & Medical Affairs, since December 2021-$2.12M
• Eli Samaha10% owner, since September 2022+$20.9M-$5.79M
• Eran BroshyDirector-$2.47M
• Jeremy T GrantDirector, since December 2023
• Richard A GrahamSVP, Research & Development-$447K
• Burton G MalkielDirector
• James Connor KellyDirector, since April 2023
• Andrew A. HindmanOfficer-$716K
• GSK plcInsider
• William D YoungDirector
• Kenneth R PitzerOfficer
• Ann BradyOfficer
• Frank PasqualoneOfficer
• Philip D WorboysOfficer-$177K
• Vijay SabesanOfficer
• Bradford J ShaferOfficer
• George M WhitesidesDirector
• Susan MolineauxDirector
• Robert V Gunderson JRDirector
• Brett K HaumannOfficer

Recent Form 3, 4, and 5 filings for TBPH

• 44d
  Former 10% Owner Weiss Asset Management Lp disposed of $126,770,020 worth of Ordinary Share $0.00001 Par Value (7,457,060 units at $17.00) (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 48d
  Director Pakianathan Deepika returned 64,074 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 48d
  Director O'Connor Donal returned 80,213 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 48d
  Director Mitchell Dean J returned 97,213 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4) to cover withholding tax

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 48d
  Director Gray Susannah returned 48,146 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 48d
  Director Smaldone Alsup Laurie returned 80,989 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 48d
  CHIEF EXECUTIVE OFFICER Winningham Rick E returned 1,726,989 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4) (for withholding tax)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 48d
  SVP & CHIEF FINANCIAL OFFICER Sawaf Aziz returned 336,841 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 48d
  SVP, DEV & HEAD OF IRE OFFICE Miller Aine returned 189,826 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 48d
  SVP, GEN COUNSEL AND SECRETARY Grimaud Brett A. returned 355,168 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy tax liability

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 48d
  SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda returned 213,476 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4) (for tax liability)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 55d
  SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda sold $226,793 worth of Ordinary Shares (13,314 units at $17.03) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 213,476 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 79d
  CHIEF EXECUTIVE OFFICER Winningham Rick E covered exercise/tax liability with 20,034 units of Ordinary Shares, decreasing direct ownership by 1% to 1,611,022 units (SEC Form 4) (for withholding tax)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 79d
  SVP & CHIEF FINANCIAL OFFICER Sawaf Aziz covered exercise/tax liability with 8,112 units of Ordinary Shares, decreasing direct ownership by 2% to 336,841 units (SEC Form 4) (tax withholding)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 79d
  SVP, DEV & HEAD OF IRE OFFICE Miller Aine covered exercise/tax liability with 6,258 units of Ordinary Shares, decreasing direct ownership by 3% to 189,826 units (SEC Form 4) to cover withholding tax

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 79d
  SVP, GEN COUNSEL AND SECRETARY Grimaud Brett A. covered exercise/tax liability with 7,952 units of Ordinary Shares, decreasing direct ownership by 2% to 355,168 units (SEC Form 4) (for tax liability)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 79d
  SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda covered exercise/tax liability with 5,667 units of Ordinary Shares, decreasing direct ownership by 2% to 226,790 units (SEC Form 4) to cover taxes

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 126d
  SEC Form 4 filed by Theravance Biopharma Inc.

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 133d
  Large owner Samaha Eli sold $5,791,555 worth of COM (336,697 units at $17.20) (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 141d
  SVP, DEV & HEAD OF IRE OFFICE Miller Aine was granted 18,750 units of Ordinary Shares, increasing direct ownership by 11% to 196,084 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 147d
  SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda sold $218,167 worth of Ordinary Shares (13,314 units at $16.39) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 232,457 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 148d
  Director Smaldone Alsup Laurie was granted 6,009 units of Ordinary Shares, increasing direct ownership by 8% to 80,989 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 148d
  Director Gray Susannah was granted 6,009 units of Ordinary Shares, increasing direct ownership by 14% to 48,146 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 148d
  Director Mitchell Dean J was granted 6,009 units of Ordinary Shares, increasing direct ownership by 7% to 97,213 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 148d
  Director O'Connor Donal was granted 6,009 units of Ordinary Shares, increasing direct ownership by 8% to 80,213 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 148d
  Director Pakianathan Deepika was granted 6,009 units of Ordinary Shares, increasing direct ownership by 10% to 64,074 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 173d
  CHIEF EXECUTIVE OFFICER Winningham Rick E covered exercise/tax liability with 20,038 units of Ordinary Shares, decreasing direct ownership by 1% to 1,631,056 units (SEC Form 4) to cover withholding tax

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 173d
  SVP & CHIEF FINANCIAL OFFICER Sawaf Aziz covered exercise/tax liability with 8,670 units of Ordinary Shares, decreasing direct ownership by 2% to 344,953 units (SEC Form 4) (withholding obligation)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 173d
  SVP, DEV & HEAD OF IRE OFFICE Miller Aine covered exercise/tax liability with 6,827 units of Ordinary Shares, decreasing direct ownership by 4% to 177,334 units (SEC Form 4) to satisfy withholding obligation

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 173d
  SVP, GEN COUNSEL AND SECRETARY Grimaud Brett A. covered exercise/tax liability with 8,829 units of Ordinary Shares, decreasing direct ownership by 2% to 363,120 units (SEC Form 4) (withholding tax)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 173d
  SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda covered exercise/tax liability with 5,678 units of Ordinary Shares, decreasing direct ownership by 2% to 245,771 units (SEC Form 4) (withholding tax)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 222d
  SEC Form 4 filed by Winningham Rick E

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 222d
  SEC Form 4 filed by Sawaf Aziz

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 222d
  SEC Form 4 filed by Grimaud Brett A.

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 222d
  SEC Form 4 filed by Farnum Rhonda

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 238d
  SEC Form 4 filed by Farnum Rhonda

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 260d
  CHIEF EXECUTIVE OFFICER Winningham Rick E covered exercise/tax liability with 74,975 units of Ordinary Shares, decreasing direct ownership by 5% to 1,576,094 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 260d
  SVP & CHIEF FINANCIAL OFFICER Sawaf Aziz covered exercise/tax liability with 20,672 units of Ordinary Shares, decreasing direct ownership by 6% to 316,123 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 260d
  SVP, DEV & HEAD OF IRE OFFICE Miller Aine covered exercise/tax liability with 16,851 units of Ordinary Shares, decreasing direct ownership by 8% to 184,161 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 260d
  SVP, GEN COUNSEL AND SECRETARY Grimaud Brett A. covered exercise/tax liability with 20,833 units of Ordinary Shares, decreasing direct ownership by 6% to 334,449 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 260d
  SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda covered exercise/tax liability with 13,929 units of Ordinary Shares, decreasing direct ownership by 5% to 263,766 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 341d
  SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda sold $582,501 worth of Ordinary Shares (31,067 units at $18.75), decreasing direct ownership by 10% to 277,695 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 345d
  Director Broshy Eran sold $590,020 worth of Ordinary Shares (29,501 units at $20.00), decreasing direct ownership by 40% to 44,703 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 352d
  SVP & CHIEF FINANCIAL OFFICER Sawaf Aziz covered exercise/tax liability with 18,627 units of Ordinary Shares, decreasing direct ownership by 5% to 336,795 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 352d
  SVP, DEV & HEAD OF IRE OFFICE Miller Aine covered exercise/tax liability with 6,989 units of Ordinary Shares, decreasing direct ownership by 3% to 201,012 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 352d
  SVP, GEN COUNSEL AND SECRETARY Grimaud Brett A. covered exercise/tax liability with 19,024 units of Ordinary Shares, decreasing direct ownership by 5% to 355,282 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 352d
  SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda covered exercise/tax liability with 9,060 units of Ordinary Shares, decreasing direct ownership by 3% to 308,762 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 355d
  CHIEF EXECUTIVE OFFICER Winningham Rick E gifted 9,900 units of Ordinary Shares, received a gift of 9,900 units of Ordinary Shares and covered exercise/tax liability with 56,817 units of Ordinary Shares, decreasing direct ownership by 4% to 1,651,069 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 363d
  Amendment: Director Broshy Eran sold $809,250 worth of Ordinary Shares (45,000 units at $17.98), decreasing direct ownership by 34% to 60,204 units (SEC Form 4)

  4/A - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 363d
  Director Broshy Eran sold $1,068,250 worth of Ordinary Shares (59,000 units at $18.11), decreasing direct ownership by 49% to 46,204 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 446d
  CHIEF EXECUTIVE OFFICER Winningham Rick E covered exercise/tax liability with 15,394 units of Ordinary Shares, decreasing direct ownership by 0.89% to 1,717,786 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 446d
  SVP & CHIEF FINANCIAL OFFICER Sawaf Aziz covered exercise/tax liability with 9,368 units of Ordinary Shares, decreasing direct ownership by 3% to 355,422 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 446d
  SVP, DEV & HEAD OF IRE OFFICE Miller Aine covered exercise/tax liability with 6,989 units of Ordinary Shares, decreasing direct ownership by 3% to 208,001 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 446d
  SVP, GEN COUNSEL AND SECRETARY Grimaud Brett A. covered exercise/tax liability with 9,762 units of Ordinary Shares, decreasing direct ownership by 3% to 374,306 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 446d
  SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda covered exercise/tax liability with 9,096 units of Ordinary Shares, decreasing direct ownership by 3% to 317,822 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 483d
  SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda sold $113,870 worth of Ordinary Shares (10,000 units at $11.39), decreasing direct ownership by 3% to 326,918 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 504d
  CHIEF EXECUTIVE OFFICER Winningham Rick E gifted 20,000 units of Ordinary Shares, decreasing direct ownership by 1% to 1,733,180 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 512d
  CHIEF EXECUTIVE OFFICER Winningham Rick E gifted 9,600 units of Ordinary Shares and received a gift of 9,600 units of Ordinary Shares, decreasing direct ownership by 0.54% to 1,753,180 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 525d
  SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda sold $264,000 worth of Ordinary Shares (24,000 units at $11.00), decreasing direct ownership by 7% to 336,918 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
• 538d
  CHIEF EXECUTIVE OFFICER Winningham Rick E covered exercise/tax liability with 15,364 units of Ordinary Shares, decreasing direct ownership by 0.86% to 1,762,780 units (SEC Form 4)

  4 - Theravance Biopharma, Inc. (0001583107) (Issuer)